Clinical Risk Factors Similar Across Rheumatic Diseases
Researchers compared the association of potential risk factors for the development of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.
Spondyloarthropathy
Contextual, Disease-Related Factors Linked to Depressive Symptoms in Ankylosing Spondylitis
Researchers aimed to identify factors related to depressive symptoms in ankylosing spondylitis and comprehend their underlying associations.
Improvement in Joint Symptoms, Pain With Tildrakizumab-asmn in Psoriatic Arthritis
Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results.
Guselkumab Demonstrates Efficacy in Biologic-Naive or TNFi-Treated Patients With Psoriatic Arthritis
Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
Smoking, Job Type, Education Level Linked to Inflammation in Axial Spondyloarthritis
Researchers investigated the relationship between smoking and imaging outcomes, including sacroiliac joints, spine, and MRI radiographs in patients with axial spondyloarthritis.
Gout May Be More Common Among Patients With Ankylosing Spondylitis Than General Population
Researchers compared the prevalence of gout in a population of patients with ankylosing spondylitis vs the general population.
FDA-Approved Biologics Appropriately Initiated as Primary Therapy for Psoriatic Arthritis
Investigators analyzed the prescribing practices for patients with psoriatic arthritis at an urban rheumatology office, with an emphasis on biologic prescribing.
Upadacitinib Meets Primary and Secondary End Points in Psoriatic Arthritis Trial
AbbVie announced positive topline data from the phase 3 SELECT-PsA 2 trial of upadacitinib (Rinvoq) in patients with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to ≥1 biologic disease modifying anti-rheumatic drugs (bDMARDs).
Baseline MRI Inflammation Not a Determinant of BMD Loss in Spondyloarthritis
Investigators evaluated the effect of magnetic resonance imaging baseline inflammation on changes in bone mineral density over the course of 5 years in patients with early spondyloarthritis.
Significant Improvement in Health-Related Quality of Life With Filgotinib in Psoriatic Arthritis
Researchers evaluated the effect of filgotinib vs placebo on the health-related quality of life in patients with psoriatic arthritis from the EQUATOR study.
-
Loading...
-
Loading...
Next post in Psoriatic Arthritis
